Zymeworks Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Zymeworks Inc's ROI in the second quarter of 2026?
Zymeworks Inc recorded a cumulative net loss of $-150 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -41.33%.

Within the Healthcare sector 432 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3460, from total ROI ranking in the first quarter of 2026 at 3969.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-3.75 %	-7.97 %	-19.94 %	-22.58 %	-23.29 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	350	443	304	355	370
Return On Investment (TTM)	-41.33 %	-27.9 %	-23.35 %	-17.37 %	-19.54 %
ZYME's Overall Ranking	# 3460	# 3969	# 3371	# 3423	# 3633
Seq. Investment Change TTM	-1.37 %	5.91 %	-4.83 %	-3.18 %	-5.69 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-150	-103	-81	-63	-74

ZYME Company Profile >> Back to ZYME Roi Comparisons >> See Annual ZYME Return On Investment

Return On Investment ZYME's Ranking
Within:	No.
Industry	# 171
Sector	# 433
Overall	# 3460

Return On Investment Statistics
High	Average	Low
42.67 %	-29.23 %	-88.95 %
(Mar 31 2023)		(Mar 31 2018)

Financial Statements
Zymeworks Inc's II. Quarter Investments	$ 350 Millions	ZYME's Balance sheet
Zymeworks Inc's II. Quarter Income	$ -45 Millions	Quarterly ZYME's Income Statement
ZYME's Income by Division		See ZYME's Income by Division

ZYME Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	304	375	525	553	317
Y / Y Investment Growth	-18.83 %	-28.63 %	-5.06 %	74.33 %	-29.92 %
Net Income in Millions	-81	-123	-119	124	-212
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-26.67 %	-32.74 %	-22.6 %	22.48 %	-66.77 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ZYME's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ZYME's Competitors
Subscribers only: Roi for Zymeworks Inc's Suppliers
Subscribers only: Return On Investment for ZYME's Customers

Other Ratios
ZYME's Roa	ZYME's Inventory Turnover Ratio	ZYME's Growth Rates	ZYME's Dividend Statistics
	ZYME's Profitability Ratios	ZYME's Asset Turnover Ratio	ZYME's Dividend Growth
ZYME's Roe	ZYME's Valuation Ratios	ZYME's Financial Strength Ratios	ZYME's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-08T22:06:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.